BridgeBio Pharma, Inc. → Eidos Therapeutics, Inc.

Stake: — Shares: —

Composite Decision Signal · PASS (LOW BASE-RATE EDGE) Conviction Score: 6/100

Passive Schedule 13G filer baseline

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

0 transactions

0 buys · 0 sales · 0 awards/exercises

Issuer Cluster

5 13D/G filings on this issuer

4 other filings besides this one

Filer Track Record

4 filings by this filer

3 other filings in the data moat

Short Interest

—

Not in latest FINRA snapshot

Other 13D/G Filings on Eidos Therapeutics, Inc.

Filed	Form	Filer	Stake	Shares
2021-01-26	SC	BridgeBio Pharma, Inc.	—	—	view →
2020-10-07	SC	RA CAPITAL MANAGEMENT, L.P.	—	—	view →
2019-07-09	SC	BridgeBio Pharma, Inc.	—	—	view →
2019-05-30	SC	BridgeBio Pharma, Inc.	—	—	view →

Other Filings by BridgeBio Pharma, Inc.

Filed	Form	Issuer	Stake	Shares
2021-01-26	SC	Eidos Therapeutics, Inc.	—	—	view →
2019-07-09	SC	Eidos Therapeutics, Inc.	—	—	view →
2019-05-30	SC	Eidos Therapeutics, Inc.	—	—	view →

Want this depth on every filing the moment it hits SEC EDGAR?

Free $0 (48h-delayed alerts) · Individual $49/mo (real-time) · Team & API $199/mo · Enterprise.

See pricing →